Holen Sie sich die Stockscreener-App
4.26
10.65%
0.41
Handel nachbörslich:
4.36
0.10
+2.35%
Schlusskurs vom Vortag:
$3.85
Offen:
$3.85
24-Stunden-Volumen:
887.79K
Relative Volume:
0.89
Marktkapitalisierung:
$354.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-95.90M
KGV:
-3.2273
EPS:
-1.32
Netto-Cashflow:
$-79.09M
1W Leistung:
+4.93%
1M Leistung:
+29.88%
6M Leistung:
-24.87%
1J Leistung:
-36.61%
1-Tages-Spanne:
$3.85
$4.39
1-Wochen-Bereich:
$3.665
$4.39
52-Wochen-Spanne:
$1.865
$11.40
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Firmenname
Terns Pharmaceuticals Inc
Sektor
Branche
Telefon
650-525-5535 EXT.101
Adresse
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Vergleichen Sie TERN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
4.26 | 354.59M | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-10-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Mizuho | Buy |
| 2023-06-07 | Eingeleitet | Jefferies | Buy |
| 2023-05-31 | Eingeleitet | ROTH MKM | Buy |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-02-07 | Eingeleitet | UBS | Buy |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-09-14 | Fortgesetzt | Goldman | Buy |
| 2021-03-02 | Eingeleitet | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Buy |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Terns Pharmaceuticals Inc Aktie (TERN) Neueste Nachrichten
Terns Pharmaceuticals’ SWOT analysis: promising pipeline faces competitive CML, obesity markets - Investing.com
SG Americas Securities LLC Purchases 380,489 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Analysts Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) PT at $15.63 - Defense World
Insider Buying: Andrew Gengos Acquires 15,000 Shares of Terns Pharmaceuticals Inc (TERN) - GuruFocus
Terns Pharmaceuticals Approves Directors and Accounting Firm - TipRanks
3 Penny Stocks Wall Street Sees With 243% Upside - 24/7 Wall St.
Squarepoint Ops LLC Has $73,000 Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday - Benzinga
Transcript : Terns Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - marketscreener.com
Two Sigma Investments LP Sells 49,567 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Bank of America Corp DE Purchases 138,661 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
ProShare Advisors LLC Acquires 8,784 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals to Participate in Upcoming June Investor C - GuruFocus
Terns Pharmaceuticals Secures Double Speaking Slots at Major Healthcare Conferences: What to Expect - Stock Titan
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences - GlobeNewswire
D. E. Shaw & Co. Inc. Increases Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Millennium Management LLC Has $8.92 Million Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential By Investing.com - Investing.com Nigeria
Nuveen Asset Management LLC Buys 617,009 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential - Investing.com
Northern Trust Corp Has $3.28 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Deutsche Bank AG Has $2.21 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
BNP Paribas Financial Markets Acquires New Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Cubist Systematic Strategies LLC Decreases Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Sold by The Manufacturers Life Insurance Company - Defense World
BMO Capital Markets Issues Pessimistic Forecast for Terns Pharmaceuticals (NASDAQ:TERN) Stock Price - Defense World
Terns Pharmaceuticals Selected for Oral Presentation at - GlobeNewswire
Terns Pharmaceuticals Selected for Oral Presentation at European - GuruFocus
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 - The Manila Times
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association ... - Bluefield Daily Telegraph
Breakthrough: New Leukemia Drug TERN-701 Outperforms Standard Treatment in Multiple Resistance Cases - Stock Titan
Terns Pharma (TERN) Price Target Lowered by BMO Capital | TERN S - GuruFocus
Pfizer (PFE): Patent Developments Affect Terns Pharmaceuticals | PFE Stock News - GuruFocus
Pfizer (PFE): Patent Developments Affect Terns Pharmaceuticals | - GuruFocus
Terns Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Dimensional Fund Advisors LP Raises Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Hsbc Holdings PLC Grows Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Terns (TERN) Advances Clinical Programs with Promising Developme - GuruFocus
BRIEF-Terns Pharmaceuticals Q1 Net Income USD -23.908 Million - TradingView
Wells Fargo & Company MN Has $227,000 Stock Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
MetLife Investment Management LLC Acquires 9,500 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
JPMorgan Chase & Co. Reduces Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Terns Pharmaceuticals Reports Inducement Grants to New Employees - GuruFocus
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) | TERN Stock News - GuruFocus
Biotech Firm Terns Awards Massive 325,000 Share Options Package to New Key Hires - Stock Titan
What is Terns Pharmaceuticals Inc (TERN) Stock Return on Shareholders’ Capital? - Sete News
Finanzdaten der Terns Pharmaceuticals Inc-Aktie (TERN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Terns Pharmaceuticals Inc-Aktie (TERN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gengos Andrew | Chief Financial Officer |
Jun 13 '25 |
Buy |
3.73 |
10,000 |
37,350 |
10,000 |
| Gengos Andrew | Chief Financial Officer |
Jun 16 '25 |
Buy |
3.95 |
5,000 |
19,732 |
15,000 |
| Kuriakose Emil | Chief Medical Officer |
Apr 01 '25 |
Sale |
2.49 |
952 |
2,366 |
53,317 |
| Jung Melita Sun | Chief Business Officer |
Nov 30 '24 |
Buy |
5.11 |
2,250 |
11,498 |
2,250 |
| Burroughs Amy L. | Chief Executive Officer |
Nov 30 '24 |
Buy |
5.11 |
510 |
2,606 |
19,609 |
| Kuriakose Emil | Chief Medical Officer |
Jan 02 '25 |
Sale |
5.71 |
4,481 |
25,607 |
54,269 |
| Vignola Mark J. | Chief Financial Officer |
Jan 06 '25 |
Sale |
5.80 |
9,059 |
52,500 |
74,752 |
| Vignola Mark J. | Chief Financial Officer |
Jan 02 '25 |
Sale |
5.72 |
8,129 |
46,524 |
83,811 |
| Quigley Jill M. | Director |
Jan 06 '25 |
Sale |
5.79 |
8,760 |
50,758 |
0 |
| Quigley Jill M. | Director |
Jan 02 '25 |
Sale |
5.72 |
6,240 |
35,702 |
8,760 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):